India, Feb. 13 -- The pharmaceutical sector continues to witness earnings-driven momentum as companies report resilient Q3 FY26 performance, supported by strong domestic demand, export traction, and improved operational efficiencies across formulations and API segments. Investors are closely tracking pharma counters that delivered healthy revenue growth and profit expansion on both QoQ and YoY basis, reflecting margin stability and improving scale advantages. Here is the list of pharma stocks that came into focus today after Q3 results

delta exchange ad Ipca Laboratories Ltd Ipca Laboratories Ltd is a fully integrated pharmaceutical company manufacturing over 350 formulations and 80 APIs across therapeutic segments. Ranked among India's ...